In this study, we deploy a framework that combines pre-clinical in vitro cell line drug response data and computational modeling of signal transduction and pharmacokinetics to unravel the dose requirements for using pan-RAF and MEK inhibition for melanoma treatment. The gene discussed is MAP2K7; the disease is melanoma.